April 18th 2024
According to results of the study, 46% of patients with giant cell arteritis administered Rinvoq achieved sustained remission from weeks 12 to 52.
Bristol Myers Squibb Reveals Promising Data for KarXT, a Potential Treatment for Schizophrenia
April 9th 2024A combination of data from the EMERGENT-4 trial and pooled data from the EMERGENT program showed the promise of KarXT (xanomeline-trospium) in providing symptom improvement for people with schizophrenia.
Navigating the CBD Research Landscape: Unveiling Best Practices in the Post-MMCREA Era
March 14th 2024Although research on cannabinoids is now allowed in a growing number of countries, there are still a number of restrictions and corresponding licenses and permits required to work with these chemicals.